 |
Popular Topics |
|
Ask The Experts |
|
IVDT Insight Blog |
|
Financial Results |
Revenues increased 9% to $93.9 million in the fourth quarter of fiscal 2010, from $86.1 million in the fourth quarter of last year. Oncology revenues increased 7% to $67.2 million in the fourth fiscal quarter, compared with $63.0 million in the prior year, while woman's health revenues grew 16% to $26.7 million this quarter, compared with $23.1 million in the fourth quarter of last year.
BRACAnalysis, Myriad's products which provide a comprehensive analysis of BRCA1 and BRCA2 genes for...
Qiagen reported that consolidated net sales for its second quarter 2010 increased 9% to $262.7 million from $240.2 million in the same quarter of 2009. Excluding the unfavorable impact from foreign currency exchange rates, net sales for the second quarter 2010 would have increased 11% from the second quarter 2009. Reported operating income for the quarter decreased 9% to $42.8 million from $46.9 million in the same quarter of 2009, and net income for the quarter increased 25% to $38.5 million...
Bio-Rad Laboratories Inc. announced financial results for the first quarter ended March 31, 2010.First-quarter reported revenues were $454.2 million, up 13.3% compared to $400.9 million reported for the first quarter of 2009. On a currency-neutral basis, quarterly revenues increased 7.9% compared to the same period last year. This increase was due to a combination of organic growth across Bio‑Rad's two main areas, life science and clinical diagnostics, and the addition of certain diagnostics...
QIAGEN NV announced the results of operations for its quarter ended March 31, 2010.
The company reported that consolidated net sales for its first quarter of 2010 increased 20% to $264.4 million from $220.9 million for the same quarter of 2009. Excluding the favorable impact from foreign currency exchange rates, net sales for the first quarter 2010 would have increased by 14% from the first quarter of 2009. Reported operating income for the quarter increased 21% to $44.7 million from $37.0...
Gen-Probe Inc. reported financial results for the first quarter of 2010, highlighted by $135.4 million of total revenues and earnings per share (EPS) of $0.48 on both a non-GAAP and GAAP basis.
In the prior year period, Gen-Probe's financial results benefited from $8.2 million of non-recurring revenue and pre-tax income associated with the renegotiation of the company's blood screening collaboration with Novartis. Excluding this benefit, non-GAAP total revenues and EPS would have increased by...
Beckman Coulter Inc. announced its results for the first quarter ended March 31, 2010 results. Reported first quarter revenue, including $115.7 million from the recent Olympus Diagnostics acquisition, was $881.1 million, up 27.4% over prior year quarter, or 23.6% in constant currency. On a constant currency basis, recurring revenue increased 23.7%. Recurring revenue, excluding the impact of Olympus, grew 8.4% in constant currency. Reported net earnings were $38.7 million, or $0.54 per fully...
Life Technologies Corp. announced results for its first quarter ending March 31, 2010. Non-GAAP revenue for the first quarter was $887 million, an increase of 13% over the $785 million reported for the first quarter of 2009. Excluding the impact of currency and completed acquisitions and divestitures, organic revenue for the quarter grew 10% over the same period in the previous year.
Other financial highlights include the following:
Non-GAAP gross margin in the first quarter was 68.3%, an...
Affymetrix Inc. reported its operating results for the first quarter of 2010. Total revenue for the quarter was $80.2 million, as compared to total revenue of $78.6 million in the first quarter of 2009.
For the first quarter of 2010, product revenue was $73.4 million, service revenue was $4.5 million, and royalties and other revenue were $2.3 million. This compares to first quarter 2009 product revenue of $64.9 million, service revenue of $11.6 million, and royalties and other revenue of $2.1...
Sigma-Aldrich's reported sales for the first quarter of 2010 were $572 million, an increase of 10.2% from the first quarter of 2009. Excluding a 5.8% benefit from favorable currency rates, first quarter organic sales growth was 4.4% driven largely by unit volume growth. Sales for the company's research business grew 8.8% on a reported basis and 2.8% organically for the first quarter of 2010. Sales for SAFC continued the momentum that began in the second half of 2009, with first quarter reported...
Enzo Biochem Inc. reported financial results for the three and six months ended January 31, 2010.
Enzo Life Sciences posted an 11% increase in total revenue, to $12.6 million for the quarter, including a 13% increase in product sales, offset by a slight decline in royalty and license income to $1.8 million. Product revenue increased due to increased products sales, driven by organic growth and the acquisition of Assay Designs Inc. (ADI) in March 2009, partially offset by reduced low...
|
Daily Buzz |
Advertisers | Privacy Policy | Contact | Subscribe | Sitemap
© Canon Communications LLC 1996-2010